About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
empagliflozin (Jardiance)
- Company
- Martin Blomberg Jensen
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- 4 recruiting
Efficacy results: Not yet reported
4 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Sep 19, 2026
Find a Clinical Trial Near Me
See recruiting studies for empagliflozin (Jardiance) and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT04447911
Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia
Not yet reported University Hospital, Basel, Switzerland 113 participants Est. completion 2026-09-15 6 sitesOther conditions: Hyponatremia, SIADH, Liver Failure, Kidney FailureView official trial listing → -
Recruiting NCT NCT07038356
Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
Not yet reported Christian Schulze 536 participants Est. completion 2027-06-30 12 sitesHeart failureView official trial listing → -
Recruiting NCT NCT07055282
SGLT2i in Kidney Stones
Not yet reported University of Chicago 32 participants Est. completion 2028-11-01 1 siteOther conditions: Kidney StonesView official trial listing → -
Recruiting NCT NCT07771010
The Effect of Empagliflozin and Metformin on Oxidative Capacity and Microvascular Reactivity of Skeletal Muscle in Patients With Type 2 Diabetes Mellitus
Not yet reported University Medical Centre Ljubljana 54 participants Est. completion 2028-07-31 1 siteOther conditions: Diabetes Type 2View official trial listing → -
Status unknown NCT NCT02284269
Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
Pharmaceuticals and Medical Devices Agency, Japan 18000 participantsType 2 diabetesView official trial listing → -
Completed NCT NCT02792400
The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors
Not yet reported University Hospital, Gentofte, Copenhagen 24 participants Est. completion 2018-07 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT02798744
SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.
Not yet reported University of Leicester 68 participants Est. completion 2019-07-30 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT02846233
Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?
Not yet reported University of California, San Francisco 22 participants Est. completion 2018-12 1 siteType 2 diabetesView official trial listing → -
Status unknown NCT NCT02964715
The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes
Not yet reported University of Malaya 25 participants Est. completion 2018-11 1 siteType 2 diabetesMASLDView official trial listing → -
Completed NCT NCT03093103
Empagliflozin and Renal Oxygenation in Healthy Volunteers
Not yet reported Centre Hospitalier Universitaire Vaudois 45 participants Est. completion 2018-12-31 1 siteOther conditions: NephropathyView official trial listing → -
Status unknown NCT NCT03433248
Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES
Not yet reported M.H.H. Kramer 66 participants Est. completion 2022-09-01 1 siteType 2 diabetesView official trial listing → -
Withdrawn NCT NCT03437330
Empagliflozin Effect on Glucose Toxicity
Not yet reported University Hospital Tuebingen Est. completion 2023-05-03 2 sitesType 2 diabetesView official trial listing → -
Completed NCT NCT03852901
Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production
Not yet reported National Institute on Aging (NIA) 21 participants Est. completion 2021-12-13 1 site Stand-aloneOther conditions: Empaglifozin, Physiological Effects of Drugs, Hypoglycemic Agents, Sodium-Glucose Transporter 2 InhibitorsView official trial listing → -
Completed NCT NCT04043702
Combination of Topiramate and Empagliflozin is Considered a Good Option for the Treatment of Obesity
Ministry of Health and Population, Egypt 200 participants Est. completion 2019-07-29 1 siteOther conditions: ObesityView official trial listing → -
Terminated NCT NCT05036317
Empagliflozin for the Treatment of Postprandial Hypoglycemia
Not yet reported University Hospital, Basel, Switzerland 40 participants Est. completion 2024-08-05 3 sitesOther conditions: Postprandial HypoglycemiaView official trial listing → -
Terminated NCT NCT05129722
Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial
Not yet reported The George Institute 3 participants Est. completion 2024-05-01 2 sitesHeart failureView official trial listing → -
Withdrawn NCT NCT05174507
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes
Not yet reported University Hospital, Basel, Switzerland Est. completion 2026-05-01Other conditions: Postprandial HypoglycemiaView official trial listing → -
Terminated NCT NCT06124924
SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot
Not yet reported University of Minnesota 1 participants Est. completion 2024-08-16 1 siteOther conditions: Acute Kidney InjuryView official trial listing → -
Completed NCT NCT07169981
Effect of Empagliflozin 10 vs 25 mg on LV Remodeling in Diabetic Patients With Anterior STEMI With Reduced LVEF
Not yet reported Ain Shams University 200 participants Est. completion 2025-06-17 1 site Stand-aloneHeart failure Other conditions: Diabete Mellitus, Remodeling, Left VentricleView official trial listing → -
Active, not recruiting NCT NCT07325435
Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
Not yet reported MaryAnn Banerji 60 participants Est. completion 2028-06-30 1 siteType 2 diabetesView official trial listing → -
Completed NCT NCT07479108
Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions
Not yet reported ADIUM 32 participants Est. completion 2024-12-11 1 siteOther conditions: BioequivalanceView official trial listing → -
Not yet recruiting NCT NCT07828002
The GranStone Trial
Not yet reported, Not yet reported Martin Blomberg Jensen 100 participants Est. completion 2029-04 1 site Stand-aloneOther conditions: Paraffinoma, Granuloma, Foreign-BodyView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Also known as: empagliflozin (Jardiance), empagliflozin (Jardiance) 25 mg
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.